PKC –mTOR pathway: a new target for rituximab therapy in follicular lymphoma
نویسندگان
چکیده
1INSERM, Unite 563, Centre de Physiopathologie de Toulouse Purpan, Université Toulouse III Paul-Sabatier, Toulouse; 2Service d’hématologie, Centre Hospitalier Universitaire (CHU) Purpan, Toulouse; 3Service d’anatomie et cytologie pathologiques, CHU Purpan, Toulouse; and 4Immunologie des Tumeurs, Institut Paoli-Calmettes, Faculté de Médecine de Marseille, Université de la Méditerranée, Marseille, France
منابع مشابه
PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma.
Previous studies have documented that, in malignant B cells, rituximab elicits a complex and not yet totally understood signaling network contributing to its antitumor effect. In this context, we investigated the role of protein kinase C zeta (PKCzeta), an atypical PKC isoform, in the cellular response to rituximab. We found that follicular lymphoma cells displayed an increase in PKCzeta expres...
متن کاملSyk-dependent mTOR activation in follicular lymphoma cells.
The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy. However, the mechanism that contributes to its regulation in B lymphomas remains unknown. This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1. Moreover, immunohistochemistry applied on lym...
متن کاملAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...
متن کاملUnique toxicities and resistance mechanisms associated with monoclonal antibody therapy.
Anti-CD20 therapy has had a truly dramatic impact on treatment and outcome of patients with follicular lymphoma. Unfortunately, the majority of responses to single-agent rituximab are incomplete, and all patients with follicular lymphoma will experience disease progression at some point following rituximab therapy. Rituximab has multiple mechanisms of inducing in vivo cytotoxicity, including an...
متن کاملIntroduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
BACKGROUND It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent retrospective studies suggest that evolving therapy has improved the outcome for follicular lymphoma patients. METHODS To evaluate the impact ...
متن کامل